EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

PHIA

24.26

+0.96%↑

Search

Almirall SA

Cerrado

Sector Salud

9.13 -0.11

Resumen

Variación precio

24h

Actual

Mínimo

9.12

Máximo

9.145

Métricas clave

By Trading Economics

Ingresos

-9.7M

-1.7M

Ventas

-18M

230M

P/B

Media del Sector

378.75

73.394

BPA

0.04

Rentabilidad por dividendo

2.19

Margen de beneficio

-0.726

Empleados

1,904

EBITDA

-44M

41M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+27.41 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.19%

3.09%

Próximas Ganancias

24 feb 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-232M

1.8B

Apertura anterior

9.24

Cierre anterior

9.13

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

129 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Almirall SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 dic 2024, 07:05 UTC

Charlas de Mercado

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparación entre iguales

Cambio de precio

Almirall SA Esperado

Precio Objetivo

By TipRanks

27.41% repunte

Estimación a 12 meses

Media 11.62 EUR  27.41%

Máximo 12.25 EUR

Mínimo 10.6 EUR

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Almirall SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.05 / 9.2Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

129 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.